KLOW - Klow - GHK-CU 50 MG + BPC 10 MG + TB500 10 MG + KPV 10 MG - 80 MG total - Research Use Only

Product definition

What is KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500)?

KLOW Blend is a quad-peptide formulation of GHK-Cu, KPV, BPC-157, and TB-500 — adding KPV's melanocortin anti-inflammatory and gut-repair mechanisms to the Glow Blend's triple-peptide tissue repair profile.

The KLOW Blend is a research formulation designed to extend the Glow Blend's triple-peptide coverage (GHK-Cu + BPC-157 + TB-500) by incorporating KPV — the C-terminal tripeptide of alpha-MSH with independent melanocortin receptor-mediated anti-inflammatory activity. KPV (Lys-Pro-Val) was identified as the pharmacologically active anti-inflammatory fragment of α-MSH, retaining the parent molecule's MC1R and MC3R binding activity with a smaller molecular footprint. In preclinical gut models, KPV has been studied for NF-κB pathway suppression in intestinal epithelial cells, reduced inflammatory cytokine production, and barrier function protection in colitis models. These gut-specific anti-inflammatory effects are mechanistically distinct from BPC-157's gut-barrier NO-system mechanism — providing two pharmacologically independent approaches to gut research in the same formulation. The full KLOW profile covers: GHK-Cu (dermal collagen, hair follicle, wound healing via copper co-factor and TGF-β), KPV (gut epithelial anti-inflammation, MC1R/MC3R signaling), BPC-157 (connective tissue angiogenesis, gut barrier integrity, NO-system), and TB-500 (systemic cell migration, cardiac repair, wound closure via actin regulation).

Research context

What does the preclinical literature say about KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500)?

The KLOW Blend was developed as an extended-coverage formulation building on the Glow Blend research rationale. The addition of KPV was driven by the recognition that the three-component Glow Blend lacked direct melanocortin receptor anti-inflammatory coverage — a mechanism with distinct documented effects in gut epithelial models that is not replicated by BPC-157's NO-system mechanism despite the functional overlap in the gut repair context. KPV's independent research profile includes studies in experimental colitis models (TNBS-induced, DSS-induced in rodents), where KPV administration reduced histological damage scores, decreased pro-inflammatory cytokine production, and preserved barrier function versus vehicle controls. These findings are mechanistically grounded in MC1R and MC3R expression in intestinal epithelial cells and macrophages — the same receptors that mediate α-MSH's systemic anti-inflammatory effects but with the accessibility of the short tripeptide fragment. For researchers studying the gut-skin axis, the KLOW Blend provides coverage of both tissue systems: KPV and BPC-157 for gut epithelial biology, GHK-Cu and TB-500 for dermal repair, with mechanistic overlap in the anti-inflammatory and wound-healing dimensions connecting the two tissue systems.